Showing 5121-5130 of 10104 results for "".
- Combination Surgical Excision/Laser Treatment Improves Outcomes, Patient Satisfaction for CMNhttps://practicaldermatology.com/news/combination-surgical-excisionlaser-treatment-improves-outcomes-patient-satisfaction-for-cmn/2459908/Combining lasers with surgical excision produces cosmetically superior results compared to laser-only treatments for small to medium congenital melanocytic nevi (CMN), according to a new review. The
- Encore Dermatology Shares Positive Pivotal Study Results for Impoyz for the Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/encore-dermatology-shares-positive-pivotal-study-results-for-impoyz-for-the-treatment-of-plaque-psoriasis/2459920/Impoyz Cream (clobetasol propionate) Cream, 0.025% demonstrated efficacy early with 14.2 percent of Impoyz patients achieving treatment success at day 8 versus 1.6 percent in the vehicle group, according to results of a pivitol study that were shared at the 15 th annual Maui Derm Conference. Trea
- New Data Show Cosentyx Improves Quality of Life in Patients Being Treated for Psoriasishttps://practicaldermatology.com/news/new-data-show-cosentyx-improves-quality-of-life-in-patients-being-treated-for-psoriasis/2459924/Novartis shared results from a pooled analysis of four Phase 3 clinical trials demonstrating patients with moderate to severe plaque psoriasis (PsO) treated with Cosentyx (secukinumab) 300mg reported improvements in mobility, self-care, and usual activities components of the EQ-5D-3L questionnair
- RealSelf Survey: 36 Percent of US Adults Are Considering Cosmetic Treatmentshttps://practicaldermatology.com/news/realself-36-percent-of-us-adults-are-considering-cosmetic-treatments/2459933/More than four in five U.S. adults want to improve their personal well-being or appearance in 2019, and 36 percent are considering cosmetic treatments, according to new RealSelf survey. Fully 82 percent of U.S. adults plan to make changes related to their personal well-being and/or appear
- New Review Highlights Comprehensive Treatment Guidelines for Severe ADhttps://practicaldermatology.com/news/new-review-highlights-comprehensive-treatment-guidelines-for-severe-ad/2459936/A team of investigators from the University of Colorado College of Nursing at CU Anschutz Medical Campus and National Jewish Health has identified comprehensive guidelines for managing severe atopic dermatitis (AD). The
- JAK Kinase Inhibitors Show Promise in Treating Alopeciahttps://practicaldermatology.com/news/jak-kinase-inhibitors-show-promise-in-treating-alopecia/2459947/UPDATED -- New research suggests selective oral JAK kinase inhibitors may play a role in treating moderate-to-severe alopecia areata (AA). The findings were presented at the Inflammatory Skin Disease Summit in Vienna, Austria. In this
- New Study Investigates Prurigo Nodularis Treatmentshttps://practicaldermatology.com/news/new-study-investigates-prurigo-nodularis-treatments/2457542/Emerging treatments such as neurokinin-1 receptor antagonists show the most promise for prurigo nodularis, according to a review in JAMA Dermatology. Neurokinin-1 receptor is a target of substance P, a medi
- AD, Suicidal Thoughts and Attempts Linkedhttps://practicaldermatology.com/news/ad-suicidal-thoughts-and-attempts-linked/2457543/Patients with eczema may be more likely to have suicidal thoughts and attempts compared to their counterparts without eczema, according to a new study in JAMA Dermatology. Res
- Asana Biosciences Gets Fast Track Designation from FDA for Dual JAK/SYK Inhibitor for ADhttps://practicaldermatology.com/news/asana-biosciences-gets-fast-track-designation-from-fda-for-dual-jaksyk-inhibitor-for-ad/2457550/The FDA has granted Fast Track designation to Asana BioSciences’ investigational oral Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK) dual inhibitor ASN002 for the treatment of moderate-to-severe atopic dermatitis. “We are pleased that the FDA has granted Fast Track
- Low 3% Keloid Recurrence Found in Multicenter Case Series of Patients Treated with SRThttps://practicaldermatology.com/news/low-3-keloid-recurrence-found-in-multicenter-case-series-of-patients-treated-with-srt/2457488/Sensus Healthcare, Inc., a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), shared positive results of a multicenter case series of patients treated with the SRT-100 following